Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, Rx only, Manufact...

FDA Recall #D-0028-2026 — Class II — October 8, 2025

Recall #D-0028-2026 Date: October 8, 2025 Classification: Class II Status: Ongoing

Product Description

Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, Rx only, Manufactured by: AstraZeneca AB, Sweden, Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. NDC 0310-1730-30

Reason for Recall

Lack of Assurance of Sterility:

Recalling Firm

ASTRAZENECA PHARMACEUTICALS — Gaithersburg, MD

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

916 pre-filled syringes

Distribution

Nationwide in the U.S

Code Information

Lot YJ0152, Expiry: 01/31/2028.

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated